摘要
目的探讨强化阿托伐他汀治疗心肌梗死后无症状心衰患者的有效性及安全性。方法选取2016年8月至2018年8月我院108例心肌梗死后无症状心衰患者并进行回顾性研究,根据就诊顺序将其分成对照组和研究组,各54例,其中对照组患者接受常规剂量(20 mg)阿托伐他汀钙片治疗,研究组患者接受强化剂量(40 mg)阿托伐他汀钙片治疗。比较两组患者的治疗效果,治疗前、后心功能、6MWD、NT-pro BNP水平变化情况以及药物不良反应发生情况。结果研究组患者的治疗总有效率为94.44%,显著高于对照组的74.07%(P<0.05)。治疗后,两组的心功能Ⅰ~Ⅱ级患者占比及6MWD均明显升高,NT-pro BNP水平明显降低,且研究组均显著优于对照组,差异具有统计学意义(P<0.05)。两组患者的药物不良反应总发生率比较,差异无统计学意义(P>0.05),且停药后均自行缓解。结论强化阿托伐他汀可有效改善患者的心功能,疗效安全,对改善心肌梗死后无症状心衰患者的预后具有积极意义。
Objective To investigate the efficacy and safety of intensive atorvastatin in the treatment of silent heart failure after myocardial infarction.Methods A total of 108 patients with silent heart failure after myocardial infarction in our hospital from August 2015 to August 2018 were selected and retrospectively studied.The patients were divided into control group and study group according to the order of treatment,with 54 cases in each group.The control group received conventional dose(20 mg) atorvastatin calcium tablets treatment,and the study group received intensive dose(40 mg) atorvastatin calcium tablets treatment.The treatment effect,cardiac function,6 MWD,the level changes of NT-proBNP before and after treatment and adverse drug reactions were compared between the two groups.Results The total effective rate of treatment in the study group was 94.44%,which was significantly higher than 74.07% in the control group(P<0.05).After treatment,the proportion of patients with cardiac function grade Ⅰ~Ⅱ and 6 MWD in the two groups increased,the level of NT-proBNP in the two groups reduced,and those in the study group were significantly better than the control group,the differences were statistically significant(P<0.05).There was no statistically significant difference in the total incidence of adverse drug reactions between the two groups(P>0.05),and all patients spontaneously relieved after drug with drawal.Conclusion Intensive atorvastatin can effectively improve the cardiac function of patients,and its curative effect is safe,which is of positive significance to improve the prognosis of patients with silent heart failure after myocardial infarction.
作者
胡建库
杨鲲
曾焱
HU Jian-ku;YANG Kun;ZENG Yan(Cardiology Department,Shaanxi Armed Police Corps Hospital,Xi'an 710054,China)
出处
《临床医学研究与实践》
2020年第5期34-35,48,共3页
Clinical Research and Practice
